Reevaluation of serum p53 antibody as a tumor marker in colorectal cancer patients

Surgery Today

Volumn 42, Issue 2, 2012, Pages 164-168

  Ochiai, Hiroki ^a,b   Ohishi, Takashi ^a   Osumi, Koji ^a   Tokuyama, Jo ^a   Urakami, Hidejirou ^a   Seki, Shikou ^a   Shimada, Atsushi ^a   Matsui, Akira ^a   Isobe, Yoh ^a   Murata, Yuya ^a   Endo, Takashi ^b   Ishii, Yoshiyuki ^b   Hasegawa, Hirotoshi ^b   Matsumoto, Sumio ^a   Kitagawa, Yuko ^b  

^a NATIONAL HOSPITAL ORGANIZATION TOKYO MEDICAL CENTER   (Japan)

^b KEIO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Colorectal cancer; Serum p53 antibody; Tumor marker

Indexed keywords

CA 19-9 ANTIGEN; CARCINOEMBRYONIC ANTIGEN; PROTEIN ANTIBODY; PROTEIN P53; PROTEIN P53 ANTIBODY; TUMOR MARKER; UNCLASSIFIED DRUG;

ADULT; AGED; ANTIBODY BLOOD LEVEL; ARTICLE; CANCER DIAGNOSIS; CANCER RISK; CANCER SCREENING; CANCER STAGING; COLORECTAL CANCER; CONTROLLED STUDY; EARLY CANCER; EARLY DIAGNOSIS; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LYMPH NODE METASTASIS; LYMPHOID TISSUE; MAJOR CLINICAL STUDY; MALE; PROTEIN EXPRESSION; RISK ASSESSMENT;

ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, NEOPLASM; CA-19-9 ANTIGEN; CARCINOEMBRYONIC ANTIGEN; COLORECTAL NEOPLASMS; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; NEOPLASM STAGING; PROGNOSIS; RETROSPECTIVE STUDIES; ROC CURVE; TUMOR MARKERS, BIOLOGICAL; TUMOR SUPPRESSOR PROTEIN P53; YOUNG ADULT;

EID: 84857642977     PISSN: 09411291     EISSN: 14362813     Source Type: Journal    
DOI: 10.1007/s00595-011-0044-1     Document Type: Article

References (22)

1. M Hollstein D Sidransky B Vogelstein CC Harris 1991 p53 mutations in human cancers Science 253 5015 49 53 1905840 10.1126/science.1905840 1:CAS:528:DyaK3MXks1Gmurg%3D (Pubitemid 21917115)
2. JM Nigro SJ Baker AC Preisinger JM Jessup R Hostetter K Cleary, et al. 1989 Mutations in the p53 gene occur in diverse human tumour types Nature (London) 342 6250 705 708 10.1038/342705a0 1:CAS:528:DyaK3cXkvFyhug%3D%3D (Pubitemid 20001591)
3. M Kawakami T Yamaguchi K Takahashi H Matsumoto M Yasutome S Horiguchi, et al. 2010 Assessment of SMAD4, p53, and Ki-67 alterations as a predictor of liver metastasis in human colorectal cancer Surg Today 40 3 245 250 20180078 10.1007/s00595-009-4028-3 1:CAS:528:DC%2BC3cXisV2lsbo%3D
4. S Bosari G Viale M Roncalli D Graziani G Borsani AK Lee, et al. 1995 p53 gene mutations, p53 protein accumulation and compartmentalization in colorectal adenocarcinoma Am J Pathol 147 3 790 798 7677190 1:CAS:528:DyaK2MXoslKjtro%3D
5. R Iggo K Gatter J Bartek D Lane AL Harris 1990 Increased expression of mutant forms of p53 oncogene in primary lung cancer Lancet 335 8691 675 679 1969059 10.1016/0140-6736(90)90801-B 1:STN:280:DyaK3c7ptVWgsQ%3D%3D (Pubitemid 20089305)
6. MC von Brevern MC Hollstein HM Cawley VM De Benedetti WP Bennett L Liang, et al. 1996 Circulating anti-p53 antibodies in esophageal cancer patients are found predominantly in individuals with p53 core domain mutations in their tumors Cancer Res 56 21 4917 4921 (Pubitemid 26374429)
7. SW Lowe S Bodis A McClatchey L Remington HE Ruley DE Fisher, et al. 1994 p53 status and the efficacy of cancer therapy in vivo Science 266 5186 807 810 7973635 10.1126/science.7973635 1:CAS:528:DyaK2MXitVGgt7w%3D (Pubitemid 24359290)
8. P Hammel K Leroy-Viard MT Chaumette J Villaudy MC Falzone D Rouillard, et al. 1999 Correlations between p53-protein accumulation, serum antibodies and gene mutation in colorectal cancer Int J Cancer 81 5 712 718 10328221 10.1002/(SICI)1097-0215(19990531)81:5<712::AID-IJC7>3.0.CO;2-0 1:CAS:528:DyaK1MXjtF2kt7Y%3D (Pubitemid 29214378)
9. R Ralhan S Arora TK Chattopadhyay NK Shukla M Mathur 2000 Circulating p53 antibodies, p53 gene mutational profile and product accumulation in esophageal squamous-cell carcinoma in India Int J Cancer 85 6 791 795 10709097 10.1002/(SICI)1097-0215(20000315)85:6<791::AID-IJC9>3.0.CO;2-K 1:CAS:528:DC%2BD3cXitVeiu7g%3D (Pubitemid 30131467)
10. JG Houbiers SH van der Burg LM van de Watering RA Tollenaar A Brand CJ van de Velde, et al. 1995 Antibodies against p53 are associated with poor prognosis of colorectal cancer Br J Cancer 72 3 637 641 7669574 10.1038/bjc.1995.386 1:CAS:528:DyaK2MXotV2ktLs%3D
11. A Takeda K Nakajima H Shimada H Imaseki W Takayama H Hayashi, et al. 1999 Clinical significance of serum p53 antibody detection on chemosensitivity assay in human colorectal cancer J Surg Oncol 71 2 112 116 10389868 10.1002/(SICI)1096-9098(199906)71:2<112::AID-JSO10>3.0.CO;2-P 1:CAS:528:DyaK1MXktlShu7g%3D (Pubitemid 29288489)
12. G Shiota M Ishida N Noguchi K Oyama Y Takano M Okubo, et al. 2000 Circulating p53 antibody in patients with colorectal cancer: relation to clinicopathologic features and survival Dig Dis Sci 45 1 122 128 10695624 10.1023/A:1005473729976 1:STN:280:DC%2BD3c7lvVWksw%3D%3D (Pubitemid 30111698)
13. R Broll M Duchrow E Oevermann C Wellm O Schwandner H Schimmelpenning, et al. 2001 p53 autoantibodies in sera of patients with a colorectal cancer and their association to p53 protein concentration and p53 immunohistochemistry in tumor tissue Int J Colorectal Dis 16 1 22 27 11317693 10.1007/s003840000263 1:STN:280:DC%2BD3MvntlCjuw%3D%3D (Pubitemid 32218973)
14. A Takeda H Shimada K Nakajima H Imaseki T Suzuki T Asano, et al. 2001 Monitoring of p53 autoantibodies after resection of colorectal cancer: relationship to operative curability Eur J Surg 167 1 50 53 11213822 10.1080/110241501750069828 1:STN:280:DC%2BD3MzitFOntQ%3D%3D (Pubitemid 32066221)
15. M Lechpammer J Lukac S Lechpammer D Kovacevic M Loda Z Kusic 2004 Humoral immune response to p53 correlates with clinical course in colorectal cancer patients during adjuvant chemotherapy Int J Colorectal Dis 19 2 114 120 14634775 10.1007/s00384-003-0553-5 (Pubitemid 38239830)
16. H Shimada T Shiratori A Takeda K Matsushita S Okazumi Y Akutsu, et al. 2009 Perioperative changes of serum p53 antibody titer is a predictor for survival in patients with esophageal squamous cell carcinoma World J Surg 33 2 272 277 19052812 10.1007/s00268-008-9821-4
17. H Shimada A Takeda M Arima S Okazumi H Matsubara Y Nabeya, et al. 2000 Serum p53 antibody is a useful tumor marker in superficial esophageal squamous cell carcinoma. Monitoring of p53 autoantibodies after resection of colorectal cancer: relationship to operative curability Cancer (Philadelphia) 89 8 1677 1683 10.1002/1097-0142(20001015)89:8<1677::AID-CNCR5>3.0.CO;2-9 1:CAS:528:DC%2BD3cXnslCht7o%3D
18. A Takeda H Shimada K Nakajima S Yoshimura T Suzuki T Asano, et al. 2001 Serum p53 antibody as a useful marker for monitoring of treatment of superficial colorectal adenocarcinoma after endoscopic resection Int J Clin Oncol 6 1 45 49 11706527 10.1007/PL00012079 1:CAS:528:DC%2BD3MXotFGgtb8%3D (Pubitemid 32230363)
19. H Shimada T Ochiai F Nomura 2003 Titration of serum p53 antibodies in 1,085 patients with various types of malignant tumors: a multiinstitutional analysis by the Japan p53 Antibody Research Group Cancer (Philadelphia) 97 3 682 689 10.1002/cncr.11092 (Pubitemid 36125846)
20. R Tang CY Yeh JY Wang CR Changchien JS Chen LL Hsieh 2009 Serum p53 antibody as tumor marker for follow-up of colorectal cancer after curative resection Ann Surg Oncol 16 9 2516 2523 19565285 10.1245/s10434-009-0578-2
21. R Tang MC Ko JY Wang CR Changchien HH Chen JS Chen, et al. 2001 Humoral response to p53 in human colorectal tumors: a prospective study of 1,209 patients Int J Cancer 94 6 859 863 11745489 10.1002/ijc.1541 1:CAS:528:DC%2BD3MXotFOku70%3D (Pubitemid 33032835)
22. Y Maehara Y Kakeji A Watanabe H Baba H Kusumoto S Kohnoe, et al. 1999 Clinical implications of serum anti-p53 antibodies for patients with gastric carcinoma Cancer (Philadelphia) 85 2 302 308 10.1002/(SICI)1097-0142(19990115) 85:2<302::AID-CNCR6>3.0.CO;2-6 1:STN:280:DyaK1M7ks1ejsw%3D%3D (Pubitemid 29051283)